ATRX and soft tissue sarcoma: Even less were the patients harboring BRCA2 or RAD51B inactivating alterations (7%), thus reinforcing the leading role of the three recurrent onco-suppressors (TP53, RB1 and ATRX) already pointed out as key drivers of soft tissue sarcoma development, also in the pathogenesis of uLMS [15].